389 related articles for article (PubMed ID: 26618853)
1. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
[TBL] [Abstract][Full Text] [Related]
2. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
[TBL] [Abstract][Full Text] [Related]
3. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
[TBL] [Abstract][Full Text] [Related]
4. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
Armstrong EP; Skrepnek GH; Sasane M; Snodgrass SM; Ballas SK
J Med Econ; 2013; 16(1):10-8. PubMed ID: 22947171
[TBL] [Abstract][Full Text] [Related]
5. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
6. Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.
Vekeman F; Cheng WY; Sasane M; Huynh L; Duh MS; Paley C; Mesa RA
Leuk Lymphoma; 2015; 56(10):2803-11. PubMed ID: 25676036
[TBL] [Abstract][Full Text] [Related]
7. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
Kang HA; Barner JC
J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
[No Abstract] [Full Text] [Related]
8. Medication adherence, healthcare costs and utilization associated with acne drugs in Medicaid enrollees with acne vulgaris.
Tan X; Al-Dabagh A; Davis SA; Lin HC; Balkrishnan R; Chang J; Feldman SR
Am J Clin Dermatol; 2013 Jun; 14(3):243-51. PubMed ID: 23572294
[TBL] [Abstract][Full Text] [Related]
9. Medical utilization and costs associated with statin adherence in Medicaid enrollees with type 2 diabetes.
Wu J; Seiber E; Lacombe VA; Nahata MC; Balkrishnan R
Ann Pharmacother; 2011 Mar; 45(3):342-9. PubMed ID: 21325098
[TBL] [Abstract][Full Text] [Related]
10. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
Payne KA; Rofail D; Baladi JF; Viala M; Abetz L; Desrosiers MP; Lordan N; Ishak K; Proskorovsky I
Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
[TBL] [Abstract][Full Text] [Related]
11. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
[TBL] [Abstract][Full Text] [Related]
12. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
Ho WL; Chung KP; Yang SS; Lu MY; Jou ST; Chang HH; Yang YL; Lin DT; Lin KH
J Formos Med Assoc; 2013 Apr; 112(4):221-9. PubMed ID: 23537869
[TBL] [Abstract][Full Text] [Related]
13. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
Candrilli SD; O'Brien SH; Ware RE; Nahata MC; Seiber EE; Balkrishnan R
Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
[TBL] [Abstract][Full Text] [Related]
15. Adherence to Iron Chelation Therapy with Deferasirox Formulations among Patients with Sickle Cell Disease and β-thalassemia.
Oyedeji CI; Crawford RD; Shah N
J Natl Med Assoc; 2021 Apr; 113(2):170-176. PubMed ID: 32892996
[TBL] [Abstract][Full Text] [Related]
16. Medicaid beneficiaries with congestive heart failure: association of medication adherence with healthcare use and costs.
Esposito D; Bagchi AD; Verdier JM; Bencio DS; Kim MS
Am J Manag Care; 2009 Jul; 15(7):437-45. PubMed ID: 19589011
[TBL] [Abstract][Full Text] [Related]
17. Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy.
Jordan L; Adams-Graves P; Kanter-Washko J; Oneal PA; Sasane M; Vekeman F; Bieri C; Magestro M; Marcellari A; Duh MS
Curr Med Res Opin; 2015 Mar; 31(3):513-23. PubMed ID: 25495135
[TBL] [Abstract][Full Text] [Related]
18. Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics.
Pilon D; Patel C; Lafeuille MH; Zhdanava M; Lin D; Côté-Sergent A; Rossi C; Lefebvre P; Joshi K
J Manag Care Spec Pharm; 2021 Jul; 27(7):904-914. PubMed ID: 34185557
[No Abstract] [Full Text] [Related]
19. Clinical and economic burden of infused iron chelation therapy in the United States.
Payne KA; Desrosiers MP; Caro JJ; Baladi JF; Lordan N; Proskorovsky I; Ishak K; Rofail D
Transfusion; 2007 Oct; 47(10):1820-9. PubMed ID: 17880607
[TBL] [Abstract][Full Text] [Related]
20. The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.
Ballas SK; Zeidan AM; Duong VH; DeVeaux M; Heeney MM
Am J Hematol; 2018 Jul; 93(7):943-952. PubMed ID: 29635754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
